GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » Future 3-5Y Total Revenue Growth Rate

EXEL (Exelixis) Future 3-5Y Total Revenue Growth Rate : 11.62 (As of Jul. 19, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Exelixis Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Exelixis's Future 3-5Y Total Revenue Growth Rate is 11.62.


Competitive Comparison of Exelixis's Future 3-5Y Total Revenue Growth Rate

For the Biotechnology subindustry, Exelixis's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exelixis's Future 3-5Y Total Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Exelixis's Future 3-5Y Total Revenue Growth Rate falls into.


;
;

Exelixis  (NAS:EXEL) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


Exelixis Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Exelixis's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Exelixis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » Future 3-5Y Total Revenue Growth Rate
Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Executives
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Patrick J. Haley officer: Sr. Vice President, Commercial 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
George Poste director 515 GALVESTON DR, REDWOOD CITY CA 94063
Christopher J. Senner officer: EVP and CFO 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Amy C. Peterson officer: EVP Prod Dev & Med Aff & CMO C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Stelios Papadopoulos director 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
Jeffrey Hessekiel officer: EVP and General Counsel 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Dana Aftab officer: CSO/EVP Disc & Trans Research EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Jack L Wyszomierski director SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000
Julie Smith director C/O RAPTOR PHARMACEUTICAL CORP, 9 COMMERCIAL BLVD, SUITE 200, NOVATO CA 94949
Bob Oliver director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Maria C Freire director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
David Edward Johnson director 590 MADISON AVENUE, NEW YORK NY 10022
Alan M Garber director 3355 MILTON COURT, MOUNTAIN VIEW CA 94040
Caligan Partners Lp director, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022